|Bid||21.51 x 900|
|Ask||21.50 x 900|
|Day's range||21.26 - 21.95|
|52-week range||18.16 - 36.48|
|Beta (5Y monthly)||2.20|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||36.89|
Shares of MacroGenics (NASDAQ: MGNX) were tanking 26.4% lower as of 11:39 a.m. EDT on Thursday. The big decline came after the company announced data from a cohort in a phase 3 study evaluating margetuximab in combination with retifanlimab in treating gastroesophageal adenocarcinoma, cancer of the stomach and esophageal junction with the stomach. MacroGenics also announced preliminary data from a phase 1 clinical study evaluating MGC018 in treating advanced solid tumors.
MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.